Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Pfizer Inc (NYSE:PFE)

34.00
Delayed Data
As of Mar 24
 -0.29 / -0.85%
Today’s Change
29.41
Today|||52-Week Range
37.39
+4.68%
Year-to-Date
Large-Cap Stocks Mostly Lower With Health Care Vote Uncertainty
Mar 24 / GuruFocus News - Paid Partner Content
CytomX Soars on Bristol-Myers Partnership
Mar 20 / TheStreet.com - Paid Partner Content
Pioneer Investments Exits Wells Fargo, Coca-Cola, Buys Walt Disney
Mar 24 / GuruFocus News - Paid Partner Content
Dow 30 Stock Roundup: Boeing Inks $3.3B U.S. Army Deal, Intel Buys Mobileye
Mar 17 / Zacks.com - Paid Partner Content
Ibex Wealth Advisors Buys Vanguard Intermediate-Termorate Bond ETF, SPDR Bloomberg Ba...
Mar 24 / GuruFocus News - Paid Partner Content
Britain's national champions can thrive without protection
Mar 17 / FT.com - Paid Partner Content
Amgen's (AMGN) Humira Biosimilar Receives Approval in EU
Mar 24 / Zacks.com - Paid Partner Content
Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in China
Mar 16 / Zacks.com - Paid Partner Content
Pfizer's Immunotherapy for Skin Cancer Gets FDA Approval
Mar 24 / Zacks.com - Paid Partner Content
Glaxo Files for Label Expansion of Influenza Vaccine in US
Mar 16 / Zacks.com - Paid Partner Content
Quadrature Capital LTD Buys The Priceline Group, Alibaba Group Holding, General Elect...
Mar 24 / GuruFocus News - Paid Partner Content
Merck's (MRK) Keytruda Gets FDA Nod for Lymphoma Indication
Mar 15 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved
Mar 24 / Zacks.com - Paid Partner Content
3 Safe Stocks to Invest In for an Aging Bull Market
Mar 15 / MotleyFool.com - Paid Partner Content
Merck KGaA Shares Spike After FDA Approves Skin Cancer Treatment
Mar 24 / TheStreet.com - Paid Partner Content
Novartis Takes Aim at Pfizer in Breast Cancer
Mar 14 / MotleyFool.com - Paid Partner Content
US Market Indexes Lower With Losses Led by Energy Stocks
Mar 23 / GuruFocus News - Paid Partner Content
Better Buy: Eli Lilly and Company vs. Pfizer
Mar 13 / MotleyFool.com - Paid Partner Content
20 Questions With Tom Vilord of Vilord Wealth Advisors
Mar 23 / GuruFocus News - Paid Partner Content
Aerie Resubmits Rhopressa NDA, Roclatan Gains Traction
Mar 13 / Zacks.com - Paid Partner Content
Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse
Mar 23 / Zacks.com - Paid Partner Content
The 19 Best-Selling Prescription Drugs of All-Time
Mar 13 / MotleyFool.com - Paid Partner Content
4 Health Care Charts Signaling Buys: Pfizer, Amgen Included
Mar 21 / TheStreet.com - Paid Partner Content
3 Big Pharma Stocks To Buy in Your 401(k)
Mar 12 / MotleyFool.com - Paid Partner Content
Nektar's Pain Drug Positive in Phase III Study; Shares Gain
Mar 21 / Zacks.com - Paid Partner Content
The 3 Most Important Numbers for Johnson & Johnson
Mar 12 / MotleyFool.com - Paid Partner Content
Is Pfizer (PFE) a Great Stock for Value Investors?
Mar 21 / Zacks.com - Paid Partner Content
Trump's pledge on drug pricing squeezes pharma stocks
Mar 07 / FT.com - Paid Partner Content
Lilly's Breast Cancer Combo Drug Phase III Results Positive
Mar 21 / Zacks.com - Paid Partner Content
Trump vows to bring drug prices 'way down'
Mar 07 / CNNMoney.com
Trump, Biogen and Amgen Hammer Healthcare ETFs
Mar 20 / Zacks.com - Paid Partner Content
Manchester mulls paying for medicines based on their efficacy
Feb 24 / FT.com - Paid Partner Content